Chinese vaccine manufacturer Sinovac said its vaccine was still effective against the Delta variant of the Coronavirus. “This vaccine does not provide 100 percent protection but can still be effective in preventing severity and death,” the company wrote, according to the China Global Times.
Wei Sheng, a professor at Tongji Medical College’s School of Public Health, Huazhong University of Science and Technology, said in an interview with CCTV that according to the latest trial results, widely administered vaccines including the Sinovac vaccine are still effective against the Delta variant.
This, he said, could be seen from the experience of preventing and controlling the Corona epidemic in Guangzhou, South China’s Guangdong Province. The risk of severe disease is greatly reduced compared to those who have not been vaccinated.
“This shows the vaccine is protective,” Wei said. So far, the majority of vaccination programs in Indonesia use the Sinovac vaccine obtained through a bilateral scheme with China.
In phase 3 clinical trials conducted in Indonesia, the Sinovac vaccine had 65 percent efficacy. A study conducted by the Ministry of Health also stated that the Sinovac vaccine was effective in reducing severe symptoms in health workers by up to 94 percent.
The Delta variant or previously known as B1617.2, which was first discovered in India, is said to be more contagious. It was feared to have the ability to ‘escape’ from the vaccine, some believe that the vaccine is still able to minimize the symptoms and risk of death from this variant.
One of them, based on research conducted by the developer of the Corona vaccine from China, Sinovac.
China has not yet provided certainty about the effectiveness of the Sinovac vaccine against infections caused by the Delta variant, either through clinical trial data or real-world use. But experts still urge the public to be injected with the Sinovac vaccine as soon as possible.
The reason, epidemiologist Zhong Nanshan explained that so far, researchers have found that the Sinovac vaccine is at least able to reduce the risk of symptomatic cases or severe symptoms in COVID-19 patients due to the Delta variant.
Another quoted from Reuters, Sinovac spokesman Liu Pei Cheng explained that based on blood samples from Sinovac vaccine recipients, the impact of the Delta variant was reduced by 3 times.
According to him, two doses of the Sinovac vaccine caused an antibody reaction against the Delta variant. However, Liu has not provided detailed data regarding the percentage of efficacy.
In comparison, a study by Public Health England (PHE) in May found that 2 doses of the Pfizer vaccine were 88 percent effective at suppressing severe symptoms due to infection with the Delta variant. While 2 doses of the AstraZeneca vaccine are said to be 60 percent effective in preventing severe symptoms due to infection with the Delta variant.